Drug intelligence / Profile preview

meglumine

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral, Intravenous, Intra-arterial, Intrathecal, Rectal
01

Overview

Meglumine is an amino sugar derived from sorbitol, chemically known as N-methyl-D-glucamine. It is primarily used as an excipient in the pharmaceutical industry and as a component in iodinated contrast media for diagnostic imaging procedures such as CT scans and X-rays. In these applications, it forms salts with various iodinated organic compounds (e.g., diatrizoate meglumine, iothalamate meglumine) to enhance their solubility and reduce toxicity. While pharmacologically inactive on its own, it plays a crucial role in the formulation of radiopaque agents that help visualize internal body structures during medical imaging[1][2][3]. It is not itself an active therapeutic agent but may be found in combination products or used to prepare certain antiprotozoal drugs (e.g., meglumine antimoniate).

Brand names
MeglumineMéglumineMegluminaMegluminum
Other names
N-methyl-D-glucamine1-deoxy-1-methylaminosorbitol

Beyond the preview

Go deeper on meglumine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on meglumine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call